|
1
|
Moehrle BM and Geiger H: Aging of
hematopoietic stem cells: DNA damage and mutations? Exp Hematol.
44:895–901. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Esposito MT and So CW: DNA damage
accumulation and repair defects in acute myeloid leukemia:
Implications for pathogenesis, disease progression, and
chemotherapy resistance. Chromosoma. 123:545–561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biechonski S, Yassin M and Milyavsky M:
DNA-damage response in hematopoietic stem cells: An evolutionary
trade-off between blood regeneration and leukemia suppression.
Carcinogenesis. 38:367–377. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iyama T and Wilson DM III: DNA repair
mechanisms in dividing and non-dividing cells. DNA Repair (Amst).
12:620–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhargava R, Onyango DO and Stark JM:
Regulation of single-strand annealing and its role in genome
maintenance. Trends Genet. 32:566–575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Symington LS: Role of RAD52 epistasis
group genes in homologous recombination and double-strand break
repair. Microbiol Mol Biol Rev. 66:630–670, table of contents.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rothenberg E, Grimme JM, Spies M and Ha T:
Human Rad52-mediated homology search and annealing occurs by
continuous interactions between overlapping nucleoprotein
complexes. Proc Natl Acad Sci USA. 105:20274–20279. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Faraoni I, Compagnone M, Lavorgna S,
Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S,
Venditti A, et al: BRCA1, PARP1 and γH2AX in acute myeloid
leukemia: Role as biomarkers of response to the PARP inhibitor
olaparib. Biochim Biophys Acta. 1852:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scardocci A, Guidi F, D'Alo' F, Gumiero D,
Fabiani E, Diruscio A, Martini M, Larocca LM, Zollino M, Hohaus S,
et al: Reduced BRCA1 expression due to promoter hypermethylation in
therapy-related acute myeloid leukaemia. Br J Cancer. 95:1108–1113.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cramer-Morales K, Nieborowska-Skorska M,
Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng
H, Roy D, et al: Personalized synthetic lethality induced by
targeting RAD52 in leukemias identified by gene mutation and
expression profile. Blood. 122:1293–1304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Panier S and Boulton SJ: Double-strand
break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol.
15:7–18. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Attikum H and Gasser SM: Crosstalk
between histone modifications during the DNA damage response.
Trends Cell Biol. 19:207–217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guan B and Zhang X: Aptamers as versatile
ligands for biomedical and pharmaceutical applications. Int J
Nanomedicine. 15:1059–1071. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borghouts C, Kunz C and Groner B: Current
strategies for the development of peptide-based anti-cancer
therapeutics. J Pept Sci. 11:713–726. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Slupianek A, Dasgupta Y, Ren SY, Gurdek E,
Donlin M, Nieborowska-Skorska M, Fleury F and Skorski T: Targeting
RAD51 phosphotyrosine-315 to prevent unfaithful recombination
repair in BCR-ABL1 leukemia. Blood. 118:1062–1068. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ciccia A and Elledge SJ: The DNA damage
response: Making it safe to play with knives. Mol Cell. 40:179–204.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stadler J and Richly H: Regulation of DNA
repair mechanisms: How the chromatin environment regulates the DNA
damage response. Int J Mol Sci. 18:17152017. View Article : Google Scholar
|
|
19
|
Gaul L, Mandl-Weber S, Baumann P, Emmerich
B and Schmidmaier R: Bendamustine induces G2 cell cycle arrest and
apoptosis in myeloma cells: The role of ATM-Chk2-Cdc25A and
ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 134:245–253. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao Z, Chen Z, Gunasekera AH, Sowin TJ,
Rosenberg SH, Fesik S and Zhang H: Chk1 mediates S and G2 arrests
through Cdc25A degradation in response to DNA-damaging agents. J
Biol Chem. 278:21767–21773. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rivlin N, Koifman G and Rotter V: p53
orchestrates between normal differentiation and cancer. Semin
Cancer Biol. 32:10–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruserud Ø, Nepstad I, Hauge M, Hatfield
KJ and Reikvam H: STAT3 as a possible therapeutic target in human
malignancies: Lessons from acute myeloid leukemia. Expert Rev
Hematol. 8:29–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al Zaid Siddiquee K and Turkson J: STAT3
as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barry SP, Townsend PA, Knight RA,
Scarabelli TM, Latchman DS and Stephanou A: STAT3 modulates the DNA
damage response pathway. Int J Exp Pathol. 91:506–514. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koganti S, Hui-Yuen J, McAllister S,
Gardner B, Grasser F, Palendira U, Tangye SG, Freeman AF and
Bhaduri-McIntosh S: STAT3 interrupts ATR-Chk1 signaling to allow
oncovirus-mediated cell proliferation. Proc Natl Acad Sci USA.
111:4946–4951. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng WW, Hu Q, Liu ZR, Chen QH, Wang WX,
Zhang HG, Zhang Q, Huang YL and Zhang XK: KDM4B promotes DNA damage
response via STAT3 signaling and is a target of CREB in colorectal
cancer cells. Mol Cell Biochem. 449:81–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Groef S, Renmans D, Cai Y, Leuckx G,
Roels S, Staels W, Gradwohl G, Baeyens L, Heremans Y, Martens GA,
et al: STAT3 modulates β-cell cycling in injured mouse pancreas and
protects against DNA damage. Cell Death Dis. 7:e22722016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
